Authors :
Michael Halim
Volume/Issue :
Volume 6 - 2021, Issue 2 - February
Google Scholar :
http://bitly.ws/9nMw
Scribd :
https://bit.ly/3uYM2lU
Abstract :
The different types and the overwhelming
number of cancer cases across the globe have prompted
scholars to pursue more effective therapies than
traditional treatments. One approach that has
demonstrated considerable progress is related to the use
of PARP inhibitors. Essentially, PARP inhibitors such as
Talazoparib, Olaparib and Rucaparib use a concept of
synthetic lethality to kill tumour cells. According to
Sebastian (2011) synthetic lethality occurs when a
deficiency in one gene expression does not cause cell
death while a collection of two or more deficiencies in
gene expression leads to cell death. PARP inhibitors
exploit this concept to eradicate tumour cells
Keywords :
PARP Inhibitors, Talazoparib, Olaparib, Rucaparib
The different types and the overwhelming
number of cancer cases across the globe have prompted
scholars to pursue more effective therapies than
traditional treatments. One approach that has
demonstrated considerable progress is related to the use
of PARP inhibitors. Essentially, PARP inhibitors such as
Talazoparib, Olaparib and Rucaparib use a concept of
synthetic lethality to kill tumour cells. According to
Sebastian (2011) synthetic lethality occurs when a
deficiency in one gene expression does not cause cell
death while a collection of two or more deficiencies in
gene expression leads to cell death. PARP inhibitors
exploit this concept to eradicate tumour cells
Keywords :
PARP Inhibitors, Talazoparib, Olaparib, Rucaparib